Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Search

Top

DAYI THERAPEUTICS INC

UEI: EGQ3LAQJS311

DAYI THERAPEUTICS INC is a federal contractor, registered under UEI EGQ3LAQJS311. It has been awarded $1,998,720 across 1 federal contract. Primary work spans Unknown NAICS. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Websitehttps://www.dayitherapeutics.com/

Address123 Main St, City, ST 12345

Registration

UEI Code

EGQ3LAQJS311

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

2XJS

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

DAYI THERAPEUTICS INC is a biopharmaceutical firm focused on the research, development, and clinical translation of novel therapeutic candidates, with an emphasis on targeted drug delivery systems and precision medicine platforms. The company’s core capabilities include preclinical pharmacology, for...

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Department Of Health And Human Services$2.0M100%

Awards by NAICS

- Unknown NAICS$2.0M100%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in DAYI THERAPEUTICS INC's top NAICS codes and agencies

DDDPlus Software Licensing and SupportThe contract entails the provision of five individual Standard licenses for DDDPlus software, covering full delivery, installation, and compatibility testing to ensure seamless integration with existing systems. License administration will be maintained throughout a four-year term, including ongoing support and compliance management. The work is performance-based with the place of performance located in Silver Spring, Maryland, under a subcontract structure, and falls under the NAICS code 511210 for software publishing. The Department of Health and Human Services is the contracting organization, with a response deadline set for August 14, 2026, and the solicitation was posted on August 4, 2026. All activities must align with federal procurement standards and deliverables must meet technical and operational requirements specified in the agreement.

Department Of Health And Human Services

POSTED

DEADLINE

GastroPlus Software Licensing and SupportThe contract awards the supply and ongoing support of 20 Standard licenses for GastroPlus software over a four-year period, encompassing full delivery, installation, and verification of compatibility with FDA systems. The provider is responsible for ensuring seamless integration into existing infrastructure and managing all aspects of license administration throughout the term. Performance is required to occur at the designated location in Silver Spring, Maryland, with the work falling under NAICS code 511210 for software publishing. The opportunity was posted on August 4, 2026, and responses are due by August 14, 2026, with the contracting entity being the Department of Health and Human Services. This subcontract supports critical regulatory and scientific operations that rely on GastroPlus for pharmacokinetic and pharmacodynamic modeling within federal health and safety contexts.

Department Of Health And Human Services

POSTED

DEADLINE

Notice of Sole Source: GastroPlus PBPK and PBBM modeling platform subscription

Solicitation # 7571TE26Q00153

The U.S. Food and Drug Administration, through the Department of Health and Human Services, intends to sole-source a firm fixed-price contract to Simulations Plus Inc. for twenty GastroPlus and five DDDPlus software licenses, used for physiologically based pharmacokinetic and physiologically based biopharmaceutics modeling in support of generic drug research. The contract spans a base year from September 1, 2026, to August 31, 2027, with up to three one-year option periods extending through August 31, 2030. Performance will occur at the FDA’s White Oak campus in Silver Spring, Maryland. The acquisition is conducted under RFO 12, allowing for non-competitive procurement of commercial products, and no set-aside applies. Responses are due by August 14, 2026, and any interested party may submit a capability statement to demonstrate their ability to supply the exact software licenses as the original equipment manufacturer or authorized reseller, which the government will review solely to determine whether competitive procurement is warranted. The contract requires the vendor to provide standard individual licenses, with no auto-renewals permitted unless explicitly authorized. Acceptance of deliverables will be conducted by the Contracting Officer’s Representative within 30 working days of delivery, verifying software functionality, compatibility with FDA systems, and compliance with technical requirements. Invoicing must be submitted electronically through the Treasury’s Invoice Processing Platform, and all invoices must include detailed supporting documentation for labor, materials, and costs. The government retains the right to reject nonconforming deliveries and will not pay for services that fail to meet agreed standards. Clauses from the FAR and HHSAR govern payment, representation, whistleblower rights, anti-lobbying, accessibility, and dispute resolution, with federal regulations taking precedence over any vendor terms. The Contracting Officer and Contract Specialist are the primary points of contact, and all vendors must be actively registered in SAM at the time of submission.

Department Of Health And Human Services

POSTED

DEADLINE

Unable to Decompose Subcontract OpportunitiesDue to a system error, the prime contract details necessary to identify or structure subcontract opportunities could not be retrieved, rendering all subcontracting analysis unavailable at this time. The solicitation is designated as a subcontract under the Department of Health and Human Services, with a posted date of August 3, 2026, and a response deadline of August 18, 2026. The place of performance is listed as Bethesda, Maryland, with a zip code of 20892, though no specific office address, point of contact, or set-aside information is provided. The NAICS code is marked as NA, and the agency and organizational designations are identical, indicating an internal system limitation. Despite the absence of actionable data for suppliers, the opportunity remains live in the system with a public view link available for reference.

Department Of Health And Human Services

POSTED

DEADLINE

Antioxidant Therapy for Smith-Lemli-Opitz Syndrone

Solicitation # NICHD-08610

The contract pertains to the development and implementation of antioxidant therapy for Smith-Lemli-Opitz Syndrome, a rare genetic disorder characterized by multiple congenital anomalies and metabolic dysfunction. The solicitation, issued under NICHD-08610 by the Department of Health and Human Services through its National Institutes of Health, invites proposals aimed at advancing targeted antioxidant interventions to mitigate the pathological effects of the condition. The opportunity was posted on August 3, 2026, with responses due by August 18, 2026, at 2:00 PM Eastern Time. The work is expected to be performed in Bethesda, Maryland, consistent with the research infrastructure of the NIH campus. All proposals must be submitted through the SAM.gov portal and should address scientific rigor, feasibility, and potential clinical impact. The primary point of contact for inquiries is Niamh Cawley, with Chung Huang as the secondary contact, both reachable via NIH email addresses. The contracting activity falls under the Department of Health and Human Services with no set-aside provisions specified, and no NAICS code is assigned, indicating flexibility in contractor categorization. Interested parties should ensure adherence to deadlines and submission requirements outlined on the official UI link linked in the posting.

Department Of Health And Human Services

POSTED

DEADLINE

Notice of Intent / Sole Source Solid Waste

Solicitation # 75H71026Q00223

The Navajo Area Indian Health Service, Shiprock Service Unit, intends to award a sole-source, firm-fixed-price contract to Navajo Sanitation for solid waste collection services at the Dzilth-Na-O-Dith-Hle Health Center in Bloomfield, New Mexico, with performance beginning September 1, 2026, and ending August 31, 2027. The procurement is justified under unusual and compelling urgency due to the contractor’s unique, uninterrupted history of providing essential waste management services at the facility, ensuring continuity of operations critical to patient care. The North American Industry Classification System code is 562111, with a small business size standard of $47 million in annual revenue. No competitive solicitation will be issued unless a respondent submits clear and convincing evidence that competition would benefit the government. Responses must be submitted in writing as a capability statement by August 17, 2026, at 10:00 a.m. MST, and must not include proprietary, classified, confidential, or sensitive information. The government is not obligated to respond to or acknowledge submissions, and failure to receive affirmative responses will result in contract award without further notice. All information provided may be used in future solicitations if competition is pursued, and any resulting solicitation will be publicly announced on SAM.gov. The point of contact for inquiries is Ken Parrish, Purchasing Agent, reachable at ken.parrish@ihs.gov.

Department Of Health And Human Services

POSTED

DEADLINE

OHS Region 11 Training and Technical Assistance Network

Solicitation # 7571MN26C00013

The Department of the Interior’s existing contract with ICF Incorporated, LLC, numbered 140D0425C0027, has been administratively transferred to the Department of Health and Human Services under a new task order, 7571MN26C00013, effective July 1, 2026. This transfer is purely administrative and does not alter the original contract’s scope of work, deliverables, ultimate value, or period of performance. The work continues under the same terms and conditions, now managed by HHS to support the OHS Region 11 Training and Technical Assistance Network, with performance based in Reston, Virginia, and administrative oversight from Washington, DC. The contract, classified under NAICS code 541611, remains unrestricted with no set-aside requirements and is fully maintained under the original contractor’s responsibility. Point of contact for inquiries includes Carla Carter and Hamed Hassanzadeh Makou at HHS.

Department Of Health And Human Services

POSTED

about 1 month ago

DEADLINE

Portfolio Management System (OPS)

Solicitation # 7571MN26F80053

The Department of the Interior’s contract GS35F523BA/140D0422F0466, originally awarded to the Community Development Institute on May 11, 2022, for the Portfolio Management System (OPS), has been administratively transferred to the Department of Health and Human Services under the new contract number GS35F523BA/7571MN26F80053, effective June 12, 2026. This transfer does not modify any existing terms, including the ultimate contract value or the period of performance, and all scope of work, deliverables, and contractual obligations remain unchanged. The contract, identified by NAICS code 541511, is managed by HHS with the primary point of contact being Amber Harris at amber.harris@hhs.gov, and the work is performed in Madison, Wisconsin, while the contracting office is located in Washington, D.C. The contract notice was posted on June 15, 2026, and the change is purely administrative, with no impact on the contractor or the execution of the project.

Department Of Health And Human Services

POSTED

about 2 months ago

DEADLINE

NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)

Solicitation # PA-27-102

This solicitation supports Small Business Technology Transfer (STTR) grants through the National Institutes of Health to fund research and development projects that advance innovative technologies with potential for commercialization, requiring a formal collaboration between a U.S.-owned small business and a nonprofit research institution. The award is made solely to the small business, regardless of where the principal investigator is employed, and projects must align with the missions of NIH, CDC, or FDA components. Funding is available for Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with Fast-Track allowing combined Phase I and II review to streamline the process. Direct to Phase II is an option for businesses that have already demonstrated technical merit without prior Phase I funding, provided the application is submitted as a new proposal, not a renewal. Only one Phase II award is permitted per Phase I project, and Phase IIB Strategic Breakthrough applications must go through a separate solicitation. Applications must focus on feasibility or R&D that supports public health goals and are subject to restrictions on clinical trials, which are not permitted under this NOFO if exclusively aligned with specific NIH institutes including NIAID, NIAMS, NIDCR, NIDDK, NIMHD, NCATS, and ORIP. The funding opportunity is part of the broader SBIR/STTR mandate, which requires NIH to set aside 0.45% of its extramural budget for STTR, ensuring support for small businesses with fewer than 500 employees. Applicants are encouraged to consult with program staff prior to submission to ensure alignment with funding priorities and to use the Assignment Request Form to suggest an appropriate awarding component, though such identification is not mandatory. The solicitation closes on August 5, 2026, and information on program details, priorities, and frequently asked questions is available through the NIH Seed Fund portal and related government strategies including the Make Our Children Healthy Again initiative.

Department of Health and Human Services

POSTED

DEADLINE

NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)

Solicitation # PA-27-100

This funding opportunity supports U.S. small businesses in advancing early-stage research and development toward commercialization through the SBIR program, administered by the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. Eligible small businesses must be U.S.-owned and operated with fewer than 500 employees and are expected to lead the majority of the technical effort, with the principal investigator primarily employed by the business. The program offers Phase I grants to establish technical feasibility, Phase II grants to advance development toward market readiness, and two special pathways: Direct to Phase II for projects with prior proof of concept but no prior Phase I award, and Fast-Track for combined Phase I and Phase II submissions reviewed concurrently to accelerate progress. All awards are granted to the small business, and commercialization must be pursued using non-SBIR funds after Phase II. The scientific scope must align with the missions of participating NIH, CDC, or FDA components, focusing on health improvement and public health innovation, with applicants encouraged to consult specific institute priorities and the White House’s Make Our Children Healthy Again Strategy. While clinical trials are permitted, they are explicitly excluded if the application aligns solely with certain NIH institutes or all FDA centers, making alignment critical for responsiveness. Applications must be submitted through the designated portal by the deadline, and while applicants are not required to specify an awarding component during submission, consultation with program staff beforehand is strongly advised to ensure proper alignment. The solicitation operates under a complete small business set-aside mandate and is open to new applications only, with no renewals accepted for Direct to Phase II submissions.

Department of Health and Human Services

POSTED

DEADLINE

SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)

Solicitation # PAR-27-098

The Commercialization Readiness Pilot (CRP) program, issued under PAR-27-098, provides late-stage research and development funding and technical assistance to U.S. small business concerns that have previously received an NIH SBIR or STTR Phase II award or a Phase IIB Strategic Breakthrough award. This initiative is designed to bridge the gap between Phase II completion and full commercialization by supporting activities that require significant outsourcing, such as regulatory strategy, intellectual property development, manufacturing optimization, pre-clinical product development, and clinical trials—though not all NIH institutes accept clinical trial proposals. The program permits substantial outsourcing to contract research organizations but requires the small business to maintain active oversight and management of all scientific, financial, and administrative aspects of the work, with justified budget allocations reflecting this role. CRP funding cannot cover FDA filing fees or include separate Technical and Business Assistance (TABA) funds. Eligible applicants must be small business concerns under 500 employees meeting SBA size standards, and proposals must align with the mission of participating NIH components. The solicitation explicitly excludes applications that propose clinical trials solely aligned with certain NIH institutes, including NHLBI, NIAID, NIDDK, and others listed, which do not accept such trials under this program. Applications are limited to Type 1 new submissions, and prior Phase II funding is mandatory for eligibility. Applicants are strongly encouraged to consult with NIH program staff before submitting to ensure alignment with the most appropriate funding mechanism, as the Phase IIB Strategic Breakthrough program (PA-27-101) may be better suited for some projects with matching fund requirements. The solicitation is active through August 5, 2026, under a total small business set-aside, and further details are available through the NIH SBIR/STTR portal.

Department of Health and Human Services

POSTED

DEADLINE

Office of Head Start Monitoring Support - Aligned Monitoring System 2.0 – Digital Strategy

Solicitation # GS35F284CA-7571MN26F80017

The contract originally awarded to Arch Systems, LLC by the Department of the Interior on March 26, 2026, under contract number 140D0425F0866, has been administratively transferred to the Department of Health and Human Services (HHS) effective March 29, 2026. The new task order number for this contract under HHS is GS35F284CA/7571MN26F80017. This transition does not affect any of the original contract’s terms, including the ultimate contract value and period of performance, nor does it change the work scope, deliverables, or any contractual obligations. The contract supports the Office of Head Start Monitoring through the Aligned Monitoring System 2.0, focusing on digital strategy enhancements. It is a total small business set-aside under NAICS code 541511 and is being administered by the Department of Health and Human Services based in Washington, DC, with performance taking place in Baltimore, Maryland. Primary points of contact for this contract at HHS are Carla Carter and Hamed Hassanzadeh Makou, who can be reached via email for any inquiries related to the contract.

Department Of Health And Human Services

POSTED

DEADLINE

Child Advocate Services Contract Transfer

Solicitation # 7571MN26C00001

The contract awarded to The Young Center For Immigrant Children’s Rights on February 17, 2023, by the Department of the Interior has been administratively transferred to the Department of Health and Human Services (HHS) as of February 26, 2026. The new contract number under HHS is 7571MN26C00001. Despite this transfer, all original terms and conditions, including the ultimate contract value and the period of performance, remain unchanged. The scope of work, deliverables, and contractual obligations also continue as initially agreed, with no modifications resulting from the transfer. This contract pertains to providing child advocate services and is classified under NAICS code 624110. The place of performance is Chicago, Illinois, while the administrative and oversight responsibilities are now within the HHS office located in Washington, DC. Points of contact for this contract include Hamed Hassanzadeh Makou and Brian Nance at HHS. This administrative action simply shifts contractual responsibility to HHS without impacting the original agreement’s substance or execution.

Department Of Health And Human Services

POSTED

DEADLINE